Type III collagen is one of the most abundant structural proteins in the human body, concentrated in tissues that need to stretch and recoil: skin, blood vessels, the gut wall, and the uterus. It is built from three identical protein chains that twist into a long rope-like helix, and it works alongside type I collagen to give organs their combination of strength and flexibility. When type III collagen is deficient or structurally abnormal, the consequences range from life-threatening arterial ruptures to chronic scarring diseases, making it far more clinically significant than its relatively low public profile suggests.
What Type III Collagen Is and How It Differs from Type I
The human body produces at least 28 types of collagen, but types I and III do most of the heavy structural lifting. Type III collagen is encoded by a single gene, COL3A1, and three copies of its protein product wind together to form the finished molecule with its characteristic long triple-helical domain.1PubMed Central. Type III collagen (COL3A1): Gene and protein structure, tissue distribution, and associated diseases Unlike type I collagen, which forms thick, stiff fibers suited to bone and tendon, type III collagen produces thinner, more compliant fibrils. In fact, when researchers mixed increasing amounts of type III collagen into type I fibrils in the lab, the resulting fibers became progressively thinner and less mechanically stiff.2PubMed Central. In vitro fibrillogenesis of tropocollagen type III in collagen type I affects its relative fibrillar topology and mechanics That difference in stiffness is not a flaw. It is precisely what allows organs like blood vessels and the vocal folds to expand and contract without tearing.
In most connective tissues, types I and III collagen do not exist independently. They co-assemble into hybrid fibrils where the ratio between the two types determines the tissue’s mechanical personality. A tendon, which must resist pulling forces, has mostly type I. An artery wall, which must absorb the pulse of every heartbeat, contains a much higher proportion of type III. This ratio is not fixed for life; it shifts during wound healing, aging, and disease, and those shifts often have clinical consequences.
Where Type III Collagen Is Found
Type III collagen is especially concentrated in tissues that need elastic properties. The skin and the walls of arteries are two of the richest sources.3PubMed. Type III collagen affects dermal and vascular collagen fibrillogenesis and tissue integrity in a mutant Col3a1 transgenic mouse model It is also present in the walls of the intestines, the uterus, lung tissue, and the lining of hollow organs throughout the body. Anywhere a tissue has to stretch under pressure and spring back, type III collagen is usually part of the structural framework.
During embryonic development, type III collagen appears early. In rat skin studied across prenatal stages, researchers found that immunoreactivity for type III collagen started weakly in the mesenchymal tissue at day 10, intensified through days 12 and 14, and was particularly clear in the basement membrane and dermal layers by mid-gestation.4PubMed Central. Immunohistochemical study of type III collagen expression during pre and post-natal rat skin morphogenesis This early presence in developing connective tissue helps explain why genetic defects in COL3A1 can cause problems that are present from birth and affect multiple organ systems simultaneously.
The Role of Cross-Linking in Fibril Quality
Making a collagen molecule is only half the battle. Once individual collagen molecules are secreted into the tissue, they need to be chemically cross-linked to one another by an enzyme called lysyl oxidase. Without that cross-linking, the fibrils form but their structure goes wrong: they develop irregular profiles and widely scattered diameters instead of the uniform, tightly packed arrangements healthy tissue requires. In laboratory tendon constructs where lysyl oxidase was blocked, the resulting fibrils looked strikingly similar to those seen in certain Ehlers-Danlos syndrome cases, and the tissue was mechanically weak.5PubMed Central. Lysyl Oxidase Activity Is Required for Ordered Collagen Fibrilogenesis by Tendon Cells This tells us that the shape and strength of collagen fibrils depend not just on which collagen types are present, but on the post-assembly processing those molecules receive.
Vascular Ehlers-Danlos Syndrome
The most dramatic disorder linked to type III collagen is vascular Ehlers-Danlos syndrome (vEDS), a rare condition caused by mutations in the COL3A1 gene. Because type III collagen is concentrated in artery walls, the intestines, and the uterus, people with vEDS face a lifelong risk of spontaneous ruptures in those organs. A Dutch national cohort study of 142 patients found that major vascular, bowel, or uterine events occurred more often and at younger ages in men than in women.6PubMed Central. Vascular Ehlers-Danlos Syndrome: A Comprehensive Natural History Study in a Dutch National Cohort of 142 Patients Aortic aneurysms and collapsed lungs were also significantly more frequent in men. Where along the collagen molecule the mutation falls matters too: variants in the first quarter of the helical domain were linked to a higher rate of aortic dissection.
The clinical challenge with vEDS is that standard surgical repairs are risky because the tissue itself is fragile. Stitches can tear through weakened blood vessel walls. Management has historically centered on surveillance, blood-pressure control, and avoiding trauma. But experimental approaches are now being explored, including RNA interference technology that can selectively silence the mutant copy of COL3A1 while leaving the healthy copy intact. In patient-derived skin cells, this approach improved collagen fibril formation and reduced the harmful effects of misfolded proteins.7PubMed Central. Current Evidence and Future Perspectives in the Medical Management of Vascular Ehlers–Danlos Syndrome: Focus on Vascular Prevention RNA editing, which corrects single-letter errors in the genetic message without permanently altering DNA, is another avenue under investigation, though delivering the editing tools specifically to blood vessels remains a major hurdle.
Type III Collagen and the Heart After a Heart Attack
When a heart attack kills a patch of heart muscle, the body replaces that dead tissue with scar, and the type of collagen in that scar determines what happens next. In the weeks following a heart attack, type III collagen levels in the non-infarcted areas of both the left and right ventricles temporarily doubled at two weeks, then fell back to normal by four weeks.8PubMed. Left and right ventricular collagen type I/III ratios and remodeling post-myocardial infarction Because type III collagen is more compliant than type I, this early burst of softer collagen may allow the ventricle some adaptive flexibility. But if the balance later tips too far toward stiff type I collagen, the heart wall becomes rigid and pumping efficiency drops, contributing to heart failure. The ratio between the two collagen types in cardiac scar tissue is now considered a relevant factor in post-heart-attack remodeling.
Tracking Fibrosis Through a Blood Test
When the body manufactures type III collagen, the protein is initially made as a longer precursor called procollagen, and short peptides are clipped off the ends before the collagen molecule is assembled into tissue. Those leftover fragments enter the bloodstream, and measuring them gives clinicians a window into how much new collagen is being deposited somewhere in the body. Two related biomarkers are used for this purpose: PIIINP (the amino-terminal propeptide) and PRO-C3 (a neoepitope generated during collagen processing).
PIIINP has been used for years to monitor liver fibrosis, particularly in patients receiving methotrexate, a drug that can cause progressive liver scarring.9PubMed. Reference interval for type III procollagen (PIIINP) using the Advia centaur PIIINP assay in adults and elderly PRO-C3 has emerged as a predictive tool in more advanced liver disease. In patients with compensated advanced chronic liver disease, a two-fold increase in PRO-C3 was associated with roughly a 2.7-fold higher risk of liver-related events like decompensation or liver cancer, and this held across two separate patient cohorts.10PubMed Central. PRO-C3 is a predictor of clinical outcomes in distinct cohorts of patients with advanced liver disease The marker also shows promise outside the liver: in patients with fatty liver disease accompanied by chronic kidney disease, PRO-C3 independently predicted the combined condition and correlated with fibrosis severity in both organs.11PubMed. Serum PRO-C3 is useful for risk prediction and fibrosis assessment in MAFLD with chronic kidney disease in an Asian cohort
The clinical appeal of these markers is straightforward: measuring collagen fragments in blood is cheaper, faster, and less invasive than a tissue biopsy. The limitation is that a rising PRO-C3 level tells you the body is laying down new type III collagen somewhere, but it does not pinpoint where. A patient with both liver disease and kidney disease, for example, could have elevated PRO-C3 from either organ or both. These tests work best when interpreted alongside imaging and other lab values rather than in isolation.
Dupuytren’s Disease and Localized Collagen Shifts
Not all type III collagen disorders are genetic. Dupuytren’s disease, which causes thickened cords of tissue to form in the palm and gradually pull fingers into a bent position, involves a striking local change in collagen composition. Normal adult palmar fascia contains virtually no type III collagen, but tissue from patients with Dupuytren’s disease is abundant in it.12PubMed. Biochemical changes in the collagen of the palmar fascia in patients with Dupuytren’s disease The ratio of type III to type I collagen rises significantly in affected tissue.13The Journal of Hand Surgery: British & European Volume. The collagen changes of dupuytren’s contracture
This shift is thought to reflect an overactive wound-healing-like process that never properly resolves. In normal wound repair, the body initially deposits a soft scaffold rich in type III collagen, then gradually replaces it with stiffer type I collagen as the scar matures. In Dupuytren’s disease, the tissue seems stuck in an early, type-III-heavy phase of remodeling, producing cords that are biochemically more like immature scar tissue than normal fascia. Why some people’s palms enter this persistent remodeling state remains unclear, though genetic susceptibility and mechanical stress both appear to play roles.
Pelvic Floor and Collagen Changes
The pelvic floor relies heavily on collagen for its structural integrity, and changes in collagen content, organization, and turnover are closely linked to pelvic organ prolapse, a condition where the bladder, uterus, or rectum drops from its normal position.14PubMed. Collagen changes in pelvic support tissues in women with pelvic organ prolapse Type III collagen’s contribution here is intuitive: pelvic support tissues need both strength and a degree of elasticity, and the balance between type I and type III collagen helps provide that. When collagen degradation outpaces production, or when the ratio between collagen types shifts in unfavorable directions, the support network weakens. Pregnancy, vaginal delivery, aging, and hormonal changes all contribute to these collagen shifts, which is why prolapse is far more common in women who have given birth and in postmenopausal women.
A Surprising Role in Cancer
One of the more unexpected areas of type III collagen research involves its relationship to tumor behavior. In a mouse model of breast cancer, researchers found that type III collagen actively suppressed several steps in the metastatic process: cancer cells grown in a collagen-III-rich environment showed reduced adhesion, invasion, and migration compared to cells grown in environments poor in type III collagen. The mechanism appeared to involve the way collagen III organizes the surrounding tissue, reducing both the density of aligned collagen fibers and the activity of tumor-associated cells that normally help cancer spread.15PubMed Central. Type III Collagen Directs Stromal Organization and Limits Metastasis in a Murine Model of Breast Cancer
Follow-up work explored whether this finding could be turned into a therapeutic strategy. When researchers supplemented tumors with collagen-III-enriched hydrogels in mice, animals with the supplemented tumors had markedly less cancer spread to the lungs compared to controls.16npj breast cancer. Prognostic and therapeutic implications of tumor-restrictive type III collagen in the breast cancer microenvironment The idea is that after a tumor is surgically removed, filling the wound bed with a collagen-III-based material might help create an environment that discourages any remaining cancer cells from migrating. This is still preclinical work in animal models, but it represents a genuinely different way of thinking about post-surgical cancer care: instead of trying to kill residual tumor cells, you engineer the tissue around them to be inhospitable to their spread.
The underlying biology makes sense when you consider collagen III’s general effect on tissue architecture. In healthy tissue, collagen III promotes a loose, well-organized fibrillar network. Aggressive tumors, by contrast, tend to create dense, highly aligned collagen tracks that cancer cells use like highways to migrate away from the primary tumor. By restoring a collagen-III-rich environment, you essentially dismantle those highways.
Why Type III Collagen Gets Overlooked
In the supplement and skincare industries, collagen products almost always emphasize types I and II: type I for skin and bones, type II for joints and cartilage. Type III collagen gets occasional billing as a skin-support ingredient, usually marketed alongside type I. But its clinical significance extends far beyond cosmetic concerns. It is central to vascular integrity, wound healing dynamics, organ fibrosis, and potentially even cancer progression. The relative neglect of type III collagen in consumer-facing health content creates a gap between what people encounter in marketing and what the research literature actually considers important.
Part of the reason for this gap is that type III collagen disorders tend to be rare (vEDS) or are attributed to other causes (fibrosis, prolapse, heart failure) without the collagen angle making it into public awareness. A patient recovering from a heart attack, for example, is unlikely to hear their cardiologist describe the role of collagen III in ventricular remodeling, even though the ratio of collagen types in their cardiac scar tissue is affecting how well their heart recovers. Similarly, a patient with progressive liver disease may undergo serial blood tests for PRO-C3 without knowing that the marker tracks the deposition of one specific collagen type that is central to their scarring process.
For researchers, however, type III collagen sits at an interesting intersection. It is common enough to matter in widespread conditions like fibrosis and wound healing, rare enough in its genetic disorders to remain understudied relative to type I, and mechanistically surprising enough in areas like oncology to continue generating new questions. The gap between clinical relevance and public recognition is wider for type III collagen than for almost any other structural protein in the body.